Company

Thiel Foundation

Investor	Rounds	Invested
No investors recorded yet. Know one?

What Thiel Foundation bought

Companies Thiel Foundation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.

Company	Kind	Announced	Price	Sources
Thiel Foundation is not recorded as having acquired anything.

People

Name	Role	Sources
Peter Thiel		Brandon BioCatalyst portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Fri 14 May 2021), Brandon BioCatalyst portfolio (Fri 14 May 2021), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon BioCatalyst portfolio (Fri 12 Jun 2020)

Coverage

Stories naming Thiel Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series A $29m

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Unnamed stage $29m

Innovative type two diabetes treatment scores $29m

Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.

Brandon BioCatalyst portfolio Fri 12 Jun 2020 Glyscend Centre of Research Excellence in Translating Nutritional Science to Good Health PayPal Royal Adelaide Hospital Thiel Foundation University of Adelaide Brandon Capital Breakout Labs Santé Ventures Dr Bob Soh Professor Chris Rayner Professor Michael Horowitz Peter Thiel

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Something wrong? Tell us